1Dunne RM, Shyn PB, Sung JC, et al. Percutaneous treatment of hepatocellular carcinoma in patients with cirrhosis: A comparison of the safety of cryoablation and radiofrequency ablation.. European Journal of Radiology, 2014, 83(4):632-638.
2Liu GJ, Ji Q, Moriyasu F, et al. Value of contrast-enhanced ultrasound using perflubutane microbubbles for diagnosing liver fibrosis and cirrhosis in rats.Ultrasound in Medicine and Biology, 2013, 39(11):2158-2165.
3Yeung LWY, Guruge KS, Taniyasu S, et al. Profiles of perfluoroalkyl substances in the liver and serum of patients With liver cancer and cirrhosis in Australia. Ecotoxicology and Environmental Safety, 2013(96):139-146.
4Gu J J, He XH, Li WT, et al. Safety and efficacy of splenic artery coil embolization for hypersplenism in liver cirrhosis. Acta Radiologica, 2012, 53(8):862-867.
5Terai S, Takami T, Yamamoto N, et al. Status and prospects of liver cirrhosis treatment by using bone marrow-derived ceils and mesenchymal cells. Tissue engineering, Part B. Reviews, 2014, 20(3):206-210.
6Zheng G, Zhang LJ, Zhong J, et al. Cerebral blood flow measured by arterial-spin labeling MRI: A useful biomarker for characterization of minimal hepatic encephalopathy in patients with cirrhosis. European Journal of Radiology, 2013, 82(11):1981-1988.
8Rauscher I, Eiber M, Ganter C, et al. Evaluation of Tlp as a potential MR biomarker for liver cirrhosis: Comparison of healthy control subjects and patients with liver cirrhosis. European Journal of Radiology, 2014, 83(6):900-904.
9Kim AY, Kim YK, Lee MW, et al. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis. Acta Radiologica, 2012, 53(8):830-838.
